{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:22Z","timestamp":1794047482162,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.285595","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T15:41:02Z","timestamp":1727365262000},"page":"498-503","source":"Crossref","is-referenced-by-count":0,"title":["Co-expression of CD69, CD49d, CD279 and CD20 in chronic lymphocytic leukemia cells is a new biomarker of active disease before or under therapy"],"prefix":"10.3324","volume":"110","author":[{"given":"Sarah","family":"Cadot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Quillet-Mary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"72431","doi-asserted-by":"crossref","unstructured":"Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021; 96(12):1679-1705.","DOI":"10.1002\/ajh.26367"},{"key":"72432","doi-asserted-by":"crossref","unstructured":"Condoluci A, Terzi Di Bergamo L, Langerbeins P. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020; 135(21):1859-1869.","DOI":"10.1182\/blood.2019003453"},{"key":"72433","doi-asserted-by":"crossref","unstructured":"Rawstron AC, Villamor N, Ritgen M. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007; 21(5):956-964.","DOI":"10.1038\/sj.leu.2404584"},{"key":"72434","doi-asserted-by":"crossref","unstructured":"Van Der Velden VHJ, Cazzaniga G, Schrauder A. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007; 21(4):604-611.","DOI":"10.1038\/sj.leu.2404586"},{"key":"72435","doi-asserted-by":"crossref","unstructured":"Scarf\u00f2 L, Heltai S, Albi E. Minimal residual disease\u2013driven treatment intensification with sequential addition of ibrutinib to venetoclax in R\/R CLL. Blood. 2022; 140(22):2348-2357.","DOI":"10.1182\/blood.2022016901"},{"key":"72436","doi-asserted-by":"crossref","unstructured":"Wang XV, Hanson CA, Tschumper RC. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021; 138(26):2810-2827.","DOI":"10.1182\/blood.2020010146"},{"key":"72437","doi-asserted-by":"crossref","unstructured":"Cadot S, Audebert C, Dion C. New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: prospective study in real-world patients and mathematical modeling. PLOS Med. 2024; 21(7):e1004430.","DOI":"10.1371\/journal.pmed.1004430"},{"key":"72438","doi-asserted-by":"crossref","unstructured":"Barrientos JC, Burger JA, Byrd JC. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leuk Lymphoma. 2019; 60(4):1000-1005.","DOI":"10.1080\/10428194.2018.1512710"},{"key":"72439","doi-asserted-by":"crossref","unstructured":"Quinquenel A, Fornecker L-M, Letestu R. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. 2019; 134(7):641-644.","DOI":"10.1182\/blood.2019000854"},{"key":"72440","doi-asserted-by":"crossref","unstructured":"Bonfiglio S, Sutton L-A, Ljungstr\u00f6m V. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib. Blood Adv. 2023; 7(12):2794-2806.","DOI":"10.1182\/bloodadvances.2022008821"},{"key":"72441","doi-asserted-by":"crossref","unstructured":"Grzywnowicz M, Karabon L, Karczmarczyk A. The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(10):2908-2913.","DOI":"10.3109\/10428194.2015.1017820"},{"key":"72442","doi-asserted-by":"crossref","unstructured":"Tissino E, Pozzo F, Benedetti D. CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. Blood. 2020; 135(15):1244-1254.","DOI":"10.1182\/blood.2019003179"},{"key":"72443","doi-asserted-by":"crossref","unstructured":"Alsadhan A, Chen J, Gaglione EM. CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy. Clin Cancer Res. 2023; 29(18):3612-3621.","DOI":"10.1158\/1078-0432.CCR-22-3217"},{"key":"72444","doi-asserted-by":"crossref","unstructured":"Del Poeta G, Del Principe MI, Zucchetto A. CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. Haematologica. 2012; 97(2):279-287.","DOI":"10.3324\/haematol.2011.052829"},{"key":"72445","doi-asserted-by":"crossref","unstructured":"Cadot S, Valle C, Tosolini M. Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse. Biomark Res. 2020; 8(1):72.","DOI":"10.1186\/s40364-020-00253-w"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285595\/77545","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285595\/78047","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11765\/77545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:19Z","timestamp":1794046039000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285595","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}